Medical Condition News

RSS
Researchers develop promising targeted strategy to treat chemo-resistant blood cancer

Researchers develop promising targeted strategy to treat chemo-resistant blood cancer

Stress related to social stigma negatively impacts mental health of autistic people

Stress related to social stigma negatively impacts mental health of autistic people

Immunotherapy with pembrolizumab extends survival in metastatic or recurrent head and neck cancer

Immunotherapy with pembrolizumab extends survival in metastatic or recurrent head and neck cancer

Immunotherapy achieves major pathological response in early-stage mismatch repair deficient colon cancer

Immunotherapy achieves major pathological response in early-stage mismatch repair deficient colon cancer

People with periodontal disease less likely to reach healthy blood pressure ranges

People with periodontal disease less likely to reach healthy blood pressure ranges

Study findings could set new standard of care for advanced anal cancer

Study findings could set new standard of care for advanced anal cancer

Duration of respiratory disturbances may better predict mortality risk from OSA

Duration of respiratory disturbances may better predict mortality risk from OSA

Immunotherapy with nivolumab and ipilimumab may improve survival in patients with MSI-high metastatic colorectal cancers

Immunotherapy with nivolumab and ipilimumab may improve survival in patients with MSI-high metastatic colorectal cancers

FOTIVDA expected to be included in new ESMO guidelines for advanced renal cell carcinoma

FOTIVDA expected to be included in new ESMO guidelines for advanced renal cell carcinoma

Genentech’s combination therapy improves outcome in patients with non-squamous non-small cell lung cancer

Genentech’s combination therapy improves outcome in patients with non-squamous non-small cell lung cancer

Phase III LONSURF study shows progression-free survival in patients with refractory metastatic gastric cancer

Phase III LONSURF study shows progression-free survival in patients with refractory metastatic gastric cancer

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Researchers produce artificial antibody capable of blocking prions in the laboratory

Researchers produce artificial antibody capable of blocking prions in the laboratory

Educational initiatives needed to improve knowledge about biosimilars in oncology

Educational initiatives needed to improve knowledge about biosimilars in oncology

Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severely active ulcerative colitis

Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severely active ulcerative colitis

Study shows potential of avelumab plus axitinib as new treatment option for patients with advanced RCC

Study shows potential of avelumab plus axitinib as new treatment option for patients with advanced RCC

Pfizer announces PALOMA-3 trial results in patients with HR+, HER2- metastatic breast cancer

Pfizer announces PALOMA-3 trial results in patients with HR+, HER2- metastatic breast cancer

LYNPARZA Phase III SOLO-1 results show improved outcome for patients with advanced BRCA-mutated ovarian cancer

LYNPARZA Phase III SOLO-1 results show improved outcome for patients with advanced BRCA-mutated ovarian cancer

Free phone app helps low-income obese patients to lose weight

Free phone app helps low-income obese patients to lose weight

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.